Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Target Price at $3.93

Pliant Therapeutics, Inc. (NASDAQ:PLRX) has been given a consensus rating of “Reduce” by the fourteen analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $3.9286.

PLRX has been the topic of a number of research reports. Wall Street Zen raised Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Pliant Therapeutics in a research report on Friday, October 10th. Piper Sandler decreased their price target on shares of Pliant Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pliant Therapeutics in a research note on Sunday, August 10th.

Pliant Therapeutics Stock Down 4.8%

Shares of NASDAQ:PLRX opened at $1.57 on Friday. Pliant Therapeutics has a 52-week low of $1.10 and a 52-week high of $15.80. The firm has a fifty day moving average of $1.60 and a 200 day moving average of $1.51. The firm has a market capitalization of $96.47 million, a PE ratio of -0.55 and a beta of 1.41. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.93 and a current ratio of 13.94.

Pliant Therapeutics (NASDAQ:PLRX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.10. As a group, research analysts anticipate that Pliant Therapeutics will post -3.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PLRX. Cormorant Asset Management LP bought a new stake in Pliant Therapeutics in the first quarter valued at approximately $4,050,000. Woodline Partners LP grew its holdings in shares of Pliant Therapeutics by 1,875.0% in the first quarter. Woodline Partners LP now owns 2,514,084 shares of the company’s stock worth $3,394,000 after purchasing an additional 2,386,789 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Pliant Therapeutics by 307.1% in the second quarter. JPMorgan Chase & Co. now owns 1,958,433 shares of the company’s stock worth $2,272,000 after buying an additional 1,477,336 shares during the period. Acadian Asset Management LLC bought a new stake in Pliant Therapeutics during the 1st quarter valued at $1,642,000. Finally, Monaco Asset Management SAM bought a new stake in Pliant Therapeutics during the 2nd quarter valued at $815,000. 97.30% of the stock is owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.